©IDOSR PUBLICATIONS

ISSN: 2579-0730

International Digital Organization for Scientific Research IDOSR JBCP/25/101.424700
IDOSR JOURNAL OF BIOLOGY, CHEMISTRY AND PHARMACY 10(1):42-47, 2025.
https://doi.org/10.59298/IDOSR/JBCP/25/101.424700

Immunomodulatory Strategies in Managing Immunosuppressive States in Infants

Tom Robert

Department of Clinical Medicine and Dentistry, Kampala International University Uganda
Email: robert.tom@studwc.kiu.ac.ug

ABSTRACT

Immunosuppressive states in infants, whether congenital or acquired, present significant clinical challenges due to increased susceptibility to infections, immune dysregulation, and higher morbidity rates. These conditions stem from congenital immunodeficiencies, prematurity, maternal factors, and medical interventions, necessitating targeted immunomodulatory strategies. Effective approaches include pharmacologic agents such as immunoglobulin replacement therapy, cytokine therapy, and corticosteroids, as well as advanced cellular therapies like hematopoietic stem cell transplantation (HSCT) and gene therapy. Additionally, vaccination strategies and microbiota-based interventions play crucial roles in immune enhancement. This review highlights current and emerging immunomodulatory interventions, emphasizing their mechanisms, efficacy, and safety. A deeper understanding of these therapies can improve clinical outcomes, reduce complications, and enhance long-term immune function in affected populations.

Keywords: Immunosuppression, Immunomodulation, Infants, Vaccination, Gene Therapy

INTRODUCTION

The neonatal immune system is inherently immature, leaving infants highly susceptible to infections, immune dysregulation, and autoimmune complications [1]. Immunosuppressive states can be congenital, as seen in primary immunodeficiencies like severe combined immunodeficiency (SCID) and Wiskott-Aldrich syndrome, or acquired due to prematurity, maternal factors, or medical interventions [2] Premature infants, for instance, exhibit impaired T-cell function, reduced antibody production, and an overall delayed immune response, increasing their vulnerability to opportunistic infections and systemic inflammation [3]. Maternal factors, including in utero exposure to infections, autoimmune diseases, or immunosuppressive therapies during pregnancy, can significantly influence neonatal immune development [4]. Additionally, infants undergoing chemotherapy, radiation, or post-transplant immunosuppression often experience secondary immunodeficiency, necessitating tailored interventions to minimize infection risk and improve immune function [5]. Effective management of immunosuppression in infants requires a delicate balance between enhancing immune responses and preventing excessive immune activation, which could lead to detrimental inflammation or autoimmunity. Immunomodulatory strategies, including pharmacologic agents, cellular therapies, vaccination approaches, and microbiota-based interventions, are critical for optimizing immune function [6] in this vulnerable population. This review explores these strategies in depth, focusing on their mechanisms, efficacy, and safety, with the goal of improving clinical outcomes and long-term health in immunocompromised infants.

Causes of Immunosuppressive States in Infants

Congenital Immunodeficiencies

Primary immunodeficiencies, such as severe combined immunodeficiency (SCID), X-linked agammaglobulinemia, and DiGeorge syndrome, result in profound immune dysfunction due to defects in T cells, B cells, or other components of the immune system [7]. These conditions lead to severe and recurrent infections, failure to thrive, and increased susceptibility to opportunistic pathogens. Early

diagnosis through newborn screening and timely intervention with hematopoietic stem cell transplantation (HSCT) or gene therapy are critical to improving survival rates [8].

Prematurity

Preterm infants exhibit an immature immune system with impaired T-cell responses, reduced production of immunoglobulins, and lower levels of maternal antibodies [9]. The underdeveloped mucosal immunity and deficits in neutrophil function increase their vulnerability to bacterial sepsis, respiratory tract infections, and necrotizing enterocolitis. Delayed exposure to maternal microbiota and deficiencies in critical nutrients such as zinc and vitamin D further compromise immune responses, necessitating tailored immunonutrition strategies and prophylactic interventions [7].

Maternal Factors

Maternal infections, autoimmune diseases, and immunosuppressive therapies during pregnancy can disrupt fetal immune development. Congenital infections such as cytomegalovirus (CMV) and HIV can impair neonatal immune function, while maternal use of corticosteroids or immunosuppressants may lead to transient or persistent immunodeficiency in newborns [10]. Placental transfer of maternal autoantibodies can also contribute to neonatal immune dysregulation, as seen in neonatal lupus [11].

Medical Interventions

Infants receiving chemotherapy, radiation, or post-transplant immunosuppression are at high risk for secondary immunodeficiency due to the depletion of lymphocytes and hematopoietic progenitor cells. These conditions necessitate infection prevention strategies [10].

Pharmacologic Immunomodulation

Immunoglobulin Replacement Therapy

Intravenous immunoglobulin (IVIG) and subcutaneous immunoglobulin (SCIG) are essential in managing infants with antibody deficiencies [12]. These therapies provide passive immunity, prevent recurrent infections, and support humoral immune function in conditions such as X-linked agammaglobulinemia and common variable immunodeficiency. IVIG is administered in hospital settings, whereas SCIG allows home-based administration, improving patient convenience and compliance [13]. These treatments are particularly beneficial in preventing severe bacterial and viral infections in immunocompromised infants.

Cytokine Therapy

Interleukin-7 (IL-7): Stimulates T-cell development in lymphopenic infants and promotes immune reconstitution after immunosuppressive treatments [14]. It has shown potential in enhancing T-cell proliferation in patients recovering from severe infections and chemotherapy-induced immunosuppression [15]. Interferon-gamma (IFN-γ): Enhances macrophage activation, which is critical in chronic granulomatous disease. IFN-γ therapy has been associated with improved pathogen clearance, particularly for intracellular bacterial and fungal infections [16]. Granulocyte Colony-Stimulating Factor (G-CSF): Indicated in neutropenic infants to increase neutrophil production, reducing the risk of severe infections. G-CSF is widely used in neonates with congenital neutropenia, sepsis, or after myelosuppressive treatments to accelerate immune recovery [17,18].

Corticosteroids and Immunosuppressants

In cases of excessive immune activation, corticosteroids (e.g., dexamethasone) and immunosuppressants (e.g., tacrolimus, cyclosporine) are used to modulate immune responses [19]. These agents help manage autoimmune cytopenias, inflammatory disorders, and graft-versus-host disease following transplantation. However, their prolonged use requires careful monitoring due to potential adverse effects, including increased infection risk, metabolic complications, and growth suppression [20].

Cellular and Gene Therapies

Hematopoietic Stem Cell Transplantation (HSCT)

HSCT remains the curative treatment for congenital immunodeficiencies, including SCID and Wiskott-Aldrich syndrome [21]. Early transplantation significantly improves survival rates and immune system reconstitution, particularly when performed before the onset of severe infections. Matched sibling donors offer the best outcomes, but haploidentical or unrelated donor transplants have been increasingly successful with advancements in conditioning regimens and graft manipulation techniques [22].

Gene Therapy

Recent breakthroughs in gene therapy have enabled targeted correction of genetic defects in primary immunodeficiencies. Lentiviral vector-based gene therapy has been successfully applied in X-linked SCID and chronic granulomatous disease, restoring functional immunity without the need for long-term immunosuppressive therapy [23,24]. Ongoing research aims to refine gene-editing techniques, including CRISPR-Cas9, to enhance precision and safety in correcting immune-related genetic disorders.

Vaccination Strategies

Tailored Vaccine Schedules

Infants with immunosuppression require individualized vaccination schedules. Non-live vaccines (e.g., inactivated influenza, pneumococcal, and meningococcal vaccines) are prioritized, while live vaccines (e.g., MMR, rotavirus) are contraindicated in those with severe immunodeficiency [25]. Post-vaccination immune responses should be closely monitored, and booster doses may be necessary to achieve adequate immunity [26].

Passive Immunization

Monoclonal antibodies, such as palivizumab for respiratory syncytial virus (RSV), provide passive immunity to high-risk infants, reducing the incidence of severe lower respiratory tract infections [27]. Advances in monoclonal antibody therapies are expanding protection against other viral and bacterial pathogens in immunocompromised infants.

Nutritional and Microbiota-Based Interventions

Probiotics and Prebiotics

The gut microbiota plays a crucial role in immune development. Probiotics containing Lactobacillus and Bifidobacterium species have shown promise in enhancing immune responses and lowering infection rates in preterm infants [28] Prebiotic supplementation may further support beneficial microbial colonization, reducing inflammation and improving gut barrier integrity [29].

Micronutrient Supplementation

Nutrients such as zinc, vitamin D, and omega-3 fatty acids are essential for immune function. Their supplementation in at-risk infants has been associated with improved immune responses, reduced infection rates, and better overall health outcomes [30]. Emerging research highlights the role of vitamin D in modulating both innate and adaptive immunity, with potential implications for infection prevention and immune-mediated disorders [31].

CONCLUSION

Immunomodulatory strategies play a crucial role in managing immunosuppressive states in infants by enhancing immune function while minimizing complications. Pharmacologic therapies, including immunoglobulin replacement and cytokine therapy, help restore immune balance, while cellular interventions such as HSCT and gene therapy offer curative potential for congenital immunodeficiencies. Tailored vaccination strategies and microbiota-based approaches further support immune resilience. Advancements in precision immunotherapy and personalized treatment strategies will continue to improve outcomes, reducing morbidity and enhancing long-term health in immunocompromised infants. Ongoing research and innovation remain essential in optimizing care for this vulnerable population.

REFERENCES

1. Tsafaras GP, Ntontsi P, Xanthou G. Advantages and Limitations of the Neonatal Immune System. Front Pediatr. 2020 Jan 28;8:5. doi: 10.3389/fped.2020.00005. PMID: 32047730; PMCID: PMC6997472.
2. Basha S, Surendran N, Pichichero M. Immune responses in neonates. Expert Rev Clin Immunol. 2014 Sep;10(9):1171-84. doi: 10.1586/1744666X.2014.942288. Epub 2014 Aug 4. PMID: 25088080; PMCID: PMC4407563.
3. Crofts KF, Alexander-Miller MA. Challenges for the Newborn Immune Response to Respiratory Virus Infection and Vaccination. *Vaccines*. 2020; 8(4):558. https://doi.org/10.3390/vaccines8040558
4. Shimizu Y, Sakata-Haga H, Saikawa Y, Hatta T. Influence of Immune System Abnormalities Caused by Maternal Immune Activation in the Postnatal Period. Cells. 2023 Feb 25;12(5):741. doi: 10.3390/cells12050741. PMID: 36899877; PMCID: PMC10001371.
5. Mario Motta, Carmen Rodriguez-Perez, Angela Tincani, Andrea Lojacono, Renata Nacinovich, Gaetano Chirico, Neonates born from mothers with autoimmune disorders, Early Human Development, 2009; 85(10):

S67-S70. https://doi.org/10.1016/j.earlhumdev.2009.08.020.

6. Piccinni, MP., Lombardelli, L., Logiodice, F. *et al.* How pregnancy can affect autoimmune diseases progression?. *Clin Mol Allergy* **14**, 11 (2016). https://doi.org/10.1186/s12948-016-0048-x
7. McCusker C, Upton J, Warrington R. Primary immunodeficiency. Allergy Asthma Clin Immunol. 2018 Sep 12;14(Suppl 2):61. doi: 10.1186/s13223-018-0290-5. PMID: 30275850; PMCID: PMC6157160.
8. Maxwell A. Fung, Smita Awasthi, Samuel T. Hwang, Joyce S. Lee, Chapter 19 - Skin biopsies: their utility to allergists and immunologists, Editor(s): Christopher Chang, Allergic and Immunologic Diseases, Academic Press, 2022, Pp 543-578. https://doi.org/10.1016/B978-0-323-95061-9.00019-9.
9. Melville JM, Moss TJ. The immune consequences of preterm birth. Front Neurosci. 2013 May 21;7:79. doi: 10.3389/fnins.2013.00079. PMID: 23734091; PMCID: PMC3659282.
10. Niewiesk S. Maternal antibodies: clinical significance, mechanism of interference with immune responses, and possible vaccination strategies. Front Immunol. 2014 Sep 16;5:446. doi: 10.3389/fimmu.2014.00446. PMID: 25278941; PMCID: PMC4165321.
11. van den Berg, E.A.M. Westerbeek, F.R.M. van der Klis, G.A.M. Berbers, R.M. van Elburg, Transplacental transport of IgG antibodies to preterm infants: A review of the literature, Early Human Development, 2011;87(2):67-72. https://doi.org/10.1016/j.earlhumdev.2010.11.003.
12. Epland, K., Suez, D. & Paris, K. A clinician's guide for administration of high-concentration and facilitated subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency diseases. *Allergy Asthma Clin Immunol* **18**, 87 (2022). https://doi.org/10.1186/s13223-022-00726-7
13. Yalcin Gungoren, E., Yorgun Altunbas, M., Dikici, U. *et al.* Insights into Patient Experiences with Facilitated Subcutaneous Immunoglobulin Therapy in Primary Immune Deficiency: A Prospective Observational Cohort. *J Clin Immunol* **44**, 169 (2024). https://doi.org/10.1007/s10875-024-01771-0
14. Morre M, Beq S. Interleukin-7 and immune reconstitution in cancer patients: a new paradigm for dramatically increasing overall survival. Target Oncol. 2012 Mar;7(1):55-68. doi: 10.1007/s11523-012-0210-4. Epub 2012 Mar 2. PMID: 22383042; PMCID: PMC3304058.
15. Bidar, F., Hamada, S., Gossez, M. *et al.* Recombinant human interleukin-7 reverses T cell exhaustion ex vivo in critically ill COVID-19 patients. *Ann. Intensive Care* **12**, 21 (2022). https://doi.org/10.1186/s13613-022-00982-1
16. A. Rakityanskaya I, S. Ryabova T, A. Kalashnikova A, S. Balasaniants G, D. Kaprin A, I. Ershov F, et al. Perspective Chapter: The Role of Interferon Gamma in Clinical Medicine [Internet]. Basic and Clinical Aspects of Interferon Gamma. IntechOpen; 2022. Available from: http://dx.doi.org/10.5772/intechopen.105476
17. Tau G, Rothman P. Biologic functions of the IFN-gamma receptors. Allergy. 1999 Dec;54(12):1233-51. doi: 10.1034/j.1398-9995.1999.00099.x. PMID: 10688427; PMCID: PMC4154595.
18. Ram Savan, Sarangan Ravichandran, Jack R. Collins, Masahiro Sakai, Howard A. Young,Structural conservation of interferon gamma among vertebrates, Cytokine & Growth Factor Reviews, 2009; 20(2): 115-124. https://doi.org/10.1016/j.cytogfr.2009.02.006.
19. Giles AJ, Hutchinson MND, Sonnemann HM, Jung J, Fecci PE, Ratnam NM, Zhang W, Song H, Bailey R, Davis D, Reid CM, Park DM, Gilbert MR. Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy. J Immunother Cancer. 2018 Jun 11;6(1):51. doi: 10.1186/s40425-018-0371-5. PMID: 29891009; PMCID: PMC5996496.
20. Hussain Y, Khan H. Immunosuppressive Drugs. Encyclopedia of Infection and Immunity. 2022:726–40. doi: 10.1016/B978-0-12-818731-9.00068-9. Epub 2022 Apr 8. PMCID: PMC8987166.
21. Cowan MJ, Neven B, Cavazanna-Calvo M, Fischer A, Puck J. Hematopoietic stem cell transplantation for severe combined immunodeficiency diseases. Biol Blood

Marrow Transplant. 2008 Jan;14(1 Suppl 1):73-5. doi: 10.1016/j.bbmt.2007.10.017. Erratum in: Biol Blood Marrow Transplant. 2008 Nov;14(11):1317-8. PMID: 18162224.

22. Albert MH, Slatter MA, Gennery AR, Güngör T, Bakunina K, Markovitch B, Hazelaar S, Sirait T, Courteille V, Aiuti A, Aleinikova OV, Balashov D, Bernardo ME, Bodova I, Bruno B, Cavazzana M, Chiesa R, Fischer A, Hauck F, Ifversen M, Kałwak K, Klein C, Kulagin A, Kupesiz A, Kuskonmaz B, Lindemans CA, Locatelli F, Lum SH, Maschan A, Meisel R, Moshous D, Porta F, Sauer MG, Sedlacek P, Schulz A, Suarez F, Vallée TC, Winiarski JH, Zecca M, Neven B, Veys P, Lankester AC. Hematopoietic stem cell transplantation for Wiskott-Aldrich syndrome: an EBMT Inborn Errors Working Party analysis. Blood. 2022 Mar 31;139(13):2066-2079. doi: 10.1182/blood.2021014687. PMID: 35100336.
23. Laberko, A., Mukhina, A., Machneva, E. *et al.* Allogeneic Hematopoietic Stem Cell Transplantation Activity in Inborn Errors of Immunity in Russian Federation. *J Clin Immunol* **43**, 1241–1249 (2023). https://doi.org/10.1007/s10875-023-01476-w
24. Marçais, A., Mahlaoui, N., Neven, B. *et al.* Curative allogeneic hematopoietic stem cell transplantation following reduced toxicity conditioning in adults with primary immunodeficiency. *Bone Marrow Transplant* **57**, 1520–1530 (2022). https://doi.org/10.1038/s41409-022-01739-x
25. Ana Karolina Barreto Berselli Marinho,Vaccination in children with immune-mediated disorders,Jornal de Pediatr 2023; 99(1): S62-S69. https://doi.org/10.1016/j.jped.2022.11.008 .
26. Pittet LF, Posfay-Barbe KM. Vaccination of immune compromised children-an overview for physicians. Eur J Pediatr. 2021 Jul;180(7):2035-2047. doi: 10.1007/s00431-021-03997-1. Epub 2021 Mar 5. PMID: 33665677; PMCID: PMC8195953.
27. Arvas A. Vaccination in patients with immunosuppression. Turk Pediatri Ars. 2014 Sep 1;49(3):181-5. doi: 10.5152/tpa.2014.2206. PMID: 26078660; PMCID: PMC4462293.
28. Wu HJ, Wu E. The role of gut microbiota in immune homeostasis and autoimmunity. Gut Microbes. 2012 Jan-Feb;3(1):4-14. doi: 10.4161/gmic.19320. Epub 2012 Jan 1. PMID: 22356853; PMCID: PMC3337124.
29. Zheng, D., Liwinski, T. & Elinav, E. Interaction between microbiota and immunity in health and disease. *Cell Res* **30**, 492–506(2020). https://doi.org/10.1038/s41422-020-0332-7
30. Yoo JY, Groer M, Dutra SVO, Sarkar A, McSkimming DI. Gut Microbiota and Immune System Interactions. *Microorganisms.* 2020; 8(10):1587. https://doi.org/10.3390/microorganisms8101587
31. Hou, K., Wu, ZX., Chen, XY. *et al.* Microbiota in health and diseases. *Sig Transduct Target Ther* **7**, 135 (2022). https://doi.org/10.1038/s41392-022-00974-4.

CITE AS: Tom Robert (2025). Immunomodulatory Strategies in Managing Immunosuppressive States in Infants. IDOSR JOURNAL OF BIOLOGY, CHEMISTRY AND PHARMACY 10(1):42-47. https://doi.org/10.59298/IDOSR/JBCP/25/101.424700